Renovator Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.80 M
as on 23-10-2024
- Paid Up Capital ₹ 1.74 M
as on 23-10-2024
- Company Age 11 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.10 M
as on 23-10-2024
- Revenue 3.02%
(FY 2023)
- Profit 189.28%
(FY 2023)
- Ebitda -4239.52%
(FY 2023)
- Net Worth 11.19%
(FY 2023)
- Total Assets 11.70%
(FY 2023)
About Renovator Pharmaceuticals
The Corporate was formerly known as Renovator Pharmaceuticals Private Limited. The Company is engaged in the Consumer Electronics & Durables Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.80 M and a paid-up capital of Rs 1.74 M.
The company currently has active open charges totaling ₹4.10 M.
Jyoti Singh and Sandeep Singh serve as directors at the Company.
- CIN/LLPIN
U29100UP2013PTC059926
- Company No.
059926
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Oct 2013
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- LocationNoida, Uttar Pradesh
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Renovator Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jyoti Singh  | Director | 02-Jun-2016 | Current |
| Sandeep Singh | Director | 07-Oct-2013 | Current |
Financial Performance of Renovator Pharmaceuticals.
Renovator Electricals Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 3.02% increase. The company also saw a substantial improvement in profitability, with a 189.28% increase in profit. The company's net worth Soared by an impressive increase of 11.19%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Renovator Pharmaceuticals?
In 2023, Renovator Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Renovator Appliances LimitedActive 11 years 5 monthsJyoti Singh and Sandeep Singh are mutual person
Renovator International Private LimitedInactive For E-Filing 7 months 29 daysJyoti Singh and Sandeep Singh are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 14 Jul 2018 | ₹4.10 M | Open |
How Many Employees Work at Renovator Pharmaceuticals?
Unlock and access historical data on people associated with Renovator Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Renovator Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Renovator Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
